| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 27, 2025 | mRNA COVID-19 Vaccines: FDA Safety Communication - FDA Approves Required Updated Warning in Labeling Regarding Myocarditis and Pericarditis Following Vaccination | AUDIENCE: Pediatrics, Pharmacy, Family Practice, Internal Medicine, Cardiology
ISSUE: FDA has required and approved updates to the Prescribing Information for Comirnaty (COVID-19 Vaccine, mRNA) manufactured by Pfizer Inc. and Spikevax (COVI... |
| Jun 26, 2025 | mRNA COVID-19 Vaccines: FDA Safety Communication - FDA Approves Required Updated Warning in Labeling Regarding Myocarditis and Pericarditis Following Vaccination | AUDIENCE: Pediatrics, Pharmacy, Family Practice, Internal Medicine, Cardiology
ISSUE: FDA has required and approved updates to the Prescribing Information for Comirnaty (COVID-19 Vaccine, mRNA) manufactured by Pfizer Inc. and Spikevax (COVI... |
| May 13, 2025 | FDA and CDC Recommend Pause in Use of Ixchiq (Chikungunya Vaccine, Live) in Individuals 60 Years of Age and Older While Postmarketing Safety Reports are Investigated: FDA Safety Communication | [Posted 05/12/2025]
AUDIENCE: Patient, Health Care Professional, Pharmacy
ISSUE: The FDA and the CDC are recommending a pause in the use of Ixchiq (Chikungunya Vaccine, Live) in individuals 60 years of age and older while the Agencies inves... |
| Mar 13, 2023 | What research shows about risks of myocarditis from COVID vaccines versus risks of heart damage from COVID | Frank Han is an assistant professor of pediatric cardiology at the University of Illinois at Chicago and Jennifer H. Huang is an associate professor of pediatric cardiology at Oregon Health & Science University.
Soon after the first COV... |
| Dec 9, 2022 | Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza | /EIN News/ -- NEW YORK and MAINZ, GERMANY, DECEMBER 9, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the companies have received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the... |
| Dec 8, 2022 | Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years | Bivalent vaccine authorized as third 3-µg dose in the three-dose primary series
Consistent COVID-19 hospitalization rates in this age group coupled with an overall surge in respiratory illnesses among children under 5 in the United States c... |
| Oct 5, 2022 | No Rise in Guillain-Barre Syndrome Cases After COVID Shots: Study | WEDNESDAY, Oct. 5, 2022 (HealthDay News) -- A new study has found no evidence that COVID-19 shots increase the incidence of Guillain-Barré syndrome, according to researchers.
"This is important because we can say that there is no signi... |
| Sep 15, 2022 | MedWatch: The FDA Safety Information and Adverse Event Reporting Program | MedWatch, the FDA’s medical product safety reporting program for health professionals, patients and consumers.
MedWatch receives reports from the public and when appropriate, publishes safety alerts for FDA-regulated products such as:
Presc... |
| Sep 15, 2022 | MedWatch Forms for FDA Safety Reporting | Voluntary Reporting For use by Health Professionals, Consumers, and Patients
Reporting can be done through our online reporting portal or by downloading, completing and then submitting FDA Form 3500 (health professional) or 3500B (consumer/... |
| Jun 17, 2022 | Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of Age | For Immediate Release: June 17, 2022
Today, the U.S. Food and Drug Administration authorized emergency use of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 to include use in children do... |
| Feb 12, 2022 | BioNTech : Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age - Form 6-K | Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age
NEW YORK, USA and MAINZ, GERMANY, February 11, 2022 - Pfizer Inc. (NYSE: PFE) and... |
| Feb 2, 2022 | BioNTech : Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request from U.S. FDA - Form 6-K | Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request from U.S. FDA
•With pediatric COVID-19 cases surpassing 10 million and a... |
| Jan 31, 2022 | Moderna : Receives Full U.S. FDA Approval for COVID-19 Vaccine Spikevax | Approval based on a comprehensive submission package including efficacy and safety data approximately six months after second dose
SPIKEVAX has received approval by regulators in more than 70 countries, including Canada, Japan, the European... |
| Jan 25, 2022 | BioNTech : Pfizer and BioNTech Publish Data from Two Laboratory Studies on COVID-19 Vaccine-induced Antibodies Ability to Neutralize SARS-CoV-2 Omicron Variant - Form 6-K | Pfizer and BioNTech Publish Data from Two Laboratory Studies on COVID-19 Vaccine-induced Antibodies Ability to Neutralize SARS-CoV-2 Omicron Variant
NEW YORK, USA and MAINZ, GERMANY, January 24, 2022 - Pfizer Inc. (NYSE: PFE) and BioNTech S... |
| Jan 25, 2022 | BioNTech : Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age - Form 6-K | Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based
COVID-19 Vaccine in Adults 18 to 55 Years of Age
•First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a boos... |
| Jan 13, 2022 | Positive Top-Line Results of Pfizer's Phase 3 Study Exploring Coadministration of PREVNAR 20 With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released | NEW YORK - Pfizer Inc. (NYSE:PFE) announced positive top-line results from a Phase 3 study (B74710126) describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in the United States 65 y... |
| Jan 7, 2022 | Johnson & Johnson : Real World Evidence Shows Johnson & Johnson COVID-19 Vaccine Demonstrates Durable Protection Against Breakthrough Infection, Hospitalization, and Intensive Care Unit Admission in the United States | NEW BRUNSWICK, N.J., January 6, 2022- Johnson & Johnson (NYSE: JNJ) (the Company) today announced new results from the largest study to date on the durability of COVID-19 vaccines in the United States (U.S.), showing that a single shot ... |
| Jan 4, 2022 | BioNTech : Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older - Form 6-K | Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older
•First emergency use authorization in the United States for a COVID-19 vaccine booster in adolescents 12 ... |
| Dec 24, 2021 | Pfizer and BioNTech Submit Updated Longer-Term Follow-Up Data of COMIRNATY in Adolescents 12 Through 15 Years of Age to EMA | NEW YORK and MAINZ, GERMANY - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that they have submitted longer-term follow-up data from the companies' pivotal Phase 3 clinical trial in 2,228 individuals 12 through 15 years o... |
| Dec 23, 2021 | Pfizer : and BioNTech Submit Updated Longer-Term Follow-Up Data of COMIRNATY® in Adolescents 12 Through 15 Years of Age to EMA | NEW YORK and MAINZ, GERMANY, December 23, 2021 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that they have submitted longer-term follow-up data from the companies' pivotal Phase 3 clinical trial in 2,228 individu... |
| Dec 21, 2021 | Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY to Help Meet Continued Need for Vaccine Supply | NEW YORK AND MAINZ, GERMANY - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced an agreement has been reached with the European Commission (EC) and its member states to exercise an option to purchase more than 200 million add... |
| Dec 17, 2021 | BioNTech : Pfizer And BioNTech Submit Supplemental Biologics License Application for U.S. FDA Approval of COMIRNATY® in Adolescents 12 Through 15 Years of Age - Form 6-K | Pfizer And BioNTech Submit Supplemental Biologics License Application for U.S. FDA Approval of COMIRNATY®
in Adolescents 12 Through 15 Years of Age
NEW YORK, USA and MAINZ, GERMANY, December 17, 2021 - Pfizer Inc. (NYSE: PFE) and BioNTech S... |
| Dec 17, 2021 | BioNTech : Pfizer and BioNTech Provide Update on Ongoing Studies of COVID-19 Vaccine - Form 6-K | Pfizer and BioNTech Provide Update on Ongoing Studies of COVID-19 Vaccine
NEW YORK, USA and MAINZ, GERMANY, December 17, 2021 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have submitted a supplemental Biolog... |
| Dec 10, 2021 | BioNTech : Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older - Form 6-K | Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older
•First emergency use authorization in the United States for a COVID-19 vaccine booster in individuals 16 years a... |
| Dec 8, 2021 | BioNTech : Pfizer and BioNTech Provide Update on Omicron Variant - Form 6-K | Pfizer and BioNTech Provide Update on Omicron Variant
•Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage), while two doses show significantl... |
| Nov 25, 2021 | Pfizer : and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 5 to | NEW YORK and MAINZ, Germany, November 25, 2021-Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European M... |
| Nov 23, 2021 | The 5 most common booster shot side effects, according to 11,290 people in the US who’ve gotten boosted | 71-year-old Frank Mallone receives a Pfizer COVID-19 booster shot at the Safeway on Capitol Hill in Washington DC, on October 4, 2021. Tom Williams/CQ-Roll Call, Inc via Getty Images
Booster shots are now being offered to all adults in the ... |
| Nov 22, 2021 | PFIZER AND BIONTECH RECEIVE EXPANDED U.S. FDA EMERGENCY USE AUTHORIZATION OF COVID-19 VACCINE BOOSTER TO INCLUDE INDIVIDUALS 18 AND OLDER | NEW YORK & MAINZ, Germany-Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a booster dose of the Pfizer-BioNTech COVI... |
| Nov 22, 2021 | Follow-Up Data from Phase 3 Trial Of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age | Pfizer-BioNTech vaccine demonstrated 100% efficacy against COVID-19 in longer-term analysis, with no serious safety concerns identified
Data will support planned submissions for full regulatory approval of the vaccine in this age group in t... |
| Nov 19, 2021 | BioNTech : PFIZER AND BIONTECH RECEIVE EXPANDED U.S. FDA EMERGENCY USE AUTHORIZATION OF COVID-19 VACCINE BOOSTER TO INCLUDE INDIVIDUALS 18 AND OLDER - Form 6-K | PFIZER AND BIONTECH RECEIVE EXPANDED U.S. FDA EMERGENCY USE AUTHORIZATION OF COVID-19 VACCINE BOOSTER TO INCLUDE INDIVIDUALS 18 AND OLDER
•Expanded authorization allows more Americans to receive a booster dose to help preserve a high-level ... |
| Nov 10, 2021 | Pfizer and BioNTech Submit Request to Amend U.S. FDA Emergency Use Authorization of Their COVID-19 Vaccine Booster to Include All Individuals 18 and Older - Form 6-K | Pfizer and BioNTech Submit Request to Amend U.S. FDA Emergency Use Authorization of Their COVID-19 Vaccine Booster to Include All Individuals 18 and Older
•Submission is based on efficacy and safety data from a Phase 3 randomized, controlle... |
| Nov 9, 2021 | PFIZER AND BIONTECH SUBMIT REQUEST TO AMEND U.S. FDA EMERGENCY USE AUTHORIZATION OF THEIR COVID-19 VACCINE BOOSTER TO INCLUDE ALL INDIVIDUALS 18 AND OLDER | PFIZER AND BIONTECH SUBMIT REQUEST TO AMEND U.S. FDA EMERGENCY USE
AUTHORIZATION OF THEIR COVID-19 VACCINE BOOSTER TO INCLUDE ALL
INDIVIDUALS 18 AND OLDER
Submission is based on efficacy and safety data from a Phase 3 randomized, controlled... |
| Nov 1, 2021 | Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years - Form 6-K | Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years
•Emergency Use A... |
| Oct 30, 2021 | Press Release : Pfizer and BioNTech Receive First -2- | Side effects reported with the vaccine include:
-- There is a remote chance that the vaccine could cause a severe allergic reaction -- A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of t... |
| Oct 28, 2021 | Press Release : Pfizer And BioNTech to Provide -2- | Emergency uses of the vaccine have not been approved or licensed by FDA, but have been authorized by FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) in individuals 12 years of age and older. Th... |
| Oct 28, 2021 | PFIZER AND BIONTECH TO PROVIDE U.S. GOVERNMENT AN ADDITIONAL 50 MILLION PEDIATRIC DOSES OF COVID-19 VACCINE TO SUPPORT FURTHER PREPAREDNESS FOR FUTURE NEEDS - Form 6-K | PFIZER AND BIONTECH TO PROVIDE U.S. GOVERNMENT AN ADDITIONAL 50 MILLION PEDIATRIC DOSES OF COVID-19 VACCINE TO SUPPORT FURTHER PREPAREDNESS FOR FUTURE NEEDS
Doses expected to be delivered by April 2022
NEW YORK, USA and MAINZ, GERMANY, Octo... |
| Oct 26, 2021 | Press Release : FDA Advisory Committee Votes in -2- | Individuals should not get the vaccine if they:
-- had a severe allergic reaction after a previous dose of this vaccine -- had a severe allergic reaction to any ingredient of this vaccine
Individuals should tell the vaccination provider abo... |
| Oct 21, 2021 | BioNTech : PFIZER ANDBIONTECH ANNOUNCE PHASE 3 TRIAL DATA SHOWING HIGH EFFICACY OF A COVID-19 VACCINE BOOSTER - Form 6-K | PFIZER ANDBIONTECH ANNOUNCE PHASE 3 TRIAL DATA SHOWING HIGH EFFICACY OF A COVID-19 VACCINE BOOSTER
•First results from any randomized, controlled COVID-19 vaccine booster trial demonstrate a relative vaccine efficacy of 95.6% against diseas... |
| Oct 21, 2021 | Moderna : Announces FDA Authorization of a Booster Dose of Moderna's COVID-19 Vaccine in the U.S. | CAMBRIDGE, Mass. - Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of... |
| Oct 21, 2021 | Press Release : Pfizer and BioNTech Announce Phase -2- | Individuals should tell the vaccination provider about all of their medical conditions, including if they:
-- have any allergies -- have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside ... |
| Oct 21, 2021 | BioNTech : Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine | First results from any randomized, controlled COVID-19 vaccine booster trial demonstrate a relative vaccine efficacy of 95.6% against disease during a period when Delta was the prevalent strain
In trial with more than 10,000 participants 16... |
| Sep 6, 2021 | Moderna : Announces Submission of Data to European Medicines Agency for its COVID-19 Vaccine Booster | CAMBRIDGE, Mass. - Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced it has submitted for a conditional marketing approval (CMA) with the European Medicines Agency (EM... |
| Aug 27, 2021 | BioNTech : Pfizer and BioNTech Announce Collaboration with Brazil's Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America (Form 6-K) | Pfizer and BioNTech Announce Collaboration with Brazil's Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America
NEW YORK, USA and MAINZ, GERMANY, August 23, 2021 - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today anno... |
| Aug 26, 2021 | Pfizer and BioNTech Announce Collaboration with Brazil's Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America | NEW YORK, USA and MAINZ, GERMANY, August 26, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a letter of intent with Eurofarma Laboratórios SA, a Brazilian biopharmaceutical company, to manufactu... |
| Aug 24, 2021 | BioNTech : Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older (Form 6-K) | Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older
• COMIRNATY is the first COVID-19 vaccine to be granted FDA approval
• Approval is based on a comprehensive submission package in... |
| Aug 24, 2021 | PFIZER : BIONTECH COVID-19 VACCINE COMIRNATY RECEIVES FULL U.S. FDA APPROVAL FOR INDIVIDUALS 16 YEARS AND OLDER | NEW YORK & MAINZ, Germany - Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for COMIRNATY (COVID-19 Vaccine, mRNA) to pre... |
| Aug 23, 2021 | BioNTech : Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older | COMIRNATY is the first COVID-19 vaccine to be granted FDA approval
Approval is based on a comprehensive submission package including six-month efficacy and safety data after second dose
More than 1.2 billion Pfizer-BioNTech doses have been ... |
| Aug 16, 2021 | Moderna : Announces FDA Authorization of Third Dose of COVID-19 Vaccine for Immunocompromised Individuals | CAMBRIDGE, Mass. - Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines announced that the U.S. Food and Drug Administration (FDA) has approved an update to the emergency use author... |
| Aug 4, 2021 | I was completely against the vaccine but changed my mind after doing my own research. Everyone should do the same. | Tom Shaw. Tom Shaw
Sign up for notifications from Insider! Stay up to date with what you want to know.
Subscribe to push notifications
Read next
NOW WATCH: How Lufthansa Cargo will ship up to 10 million COVID-19 vaccine doses a day
Vaccine ... |
| Jun 30, 2021 | President of United States : V-safe COVID-19 Vaccine Pregnancy Registry | As of June 28, 2021, more than 128 thousand v-safe participants have indicated they were pregnant at the time they received COVID-19 vaccination. CDC is currently enrolling eligible participants and analyzing data to better understand how C... |
| Jun 30, 2021 | FDA Food and Drug Administration : Learn More About COVID-19 Vaccines From the FDA | Español中文한국의TagalogTiếng Việt
The U.S. Food and Drug Administration has authorized three COVID-19 vaccines for emergency use. The vaccines are:
Pfizer BioNTech COVID-19 Vaccine
Fact sheet for recipients
Frequently asked questions
Moderna CO... |
| Jun 25, 2021 | FDA Food and Drug Administration : Learn More About COVID-19 Vaccines From the FDA | Español中文한국의TagalogTiếng Việt
The U.S. Food and Drug Administration has authorized three COVID-19 vaccines for emergency use. The vaccines are:
Pfizer BioNTech COVID-19 Vaccine
Fact sheet for recipients
Frequently asked questions
Moderna CO... |
| Jun 17, 2021 | President of United States : V-safe COVID-19 Vaccine Pregnancy Registry | As of June 14, 2021, more than 124 thousand v-safe participants have indicated they were pregnant at the time they received COVID-19 vaccination. CDC is currently enrolling eligible participants and analyzing data to better understand how C... |
| Jun 9, 2021 | President of United States : V-safe COVID-19 Vaccine Pregnancy Registry | As of June 7, 2021, more than 123 thousand v-safe participants have indicated they were pregnant at the time they received COVID-19 vaccination. CDC is currently enrolling eligible participants and analyzing data to better understand how CO... |
| Jun 2, 2021 | President of United States : V-safe COVID-19 Vaccine Pregnancy Registry | As of May 31, 2021, more than 121 thousand v-safe participants have indicated they were pregnant at the time they received COVID-19 vaccination. CDC is currently enrolling eligible participants and analyzing data to better understand how CO... |
| Apr 22, 2021 | JOHNSON & JOHNSON
Johnson & Johnson : Single-Shot COVID-19 Vaccine Phase 3 Data Published in New England Journal of Medicine | NEW BRUNSWICK, N.J., April 21, 2021- Johnson & Johnson (the Company) today announced publication in the New England Journal of Medicine of primary data from the Phase 3 ENSEMBLE clinical trial for its single-dose COVID-19 vaccine, devel... |
| Apr 13, 2021 | FDA & CDC “pause” J&J Covid-19 vaccine to launch inquiry into rare blood clot cases | Federal health officials are asking clinicians to “pause” dosing of Johnson & Johnson’s Covid-19 vaccine following reports of blood clots in six people out of the more than 6.8 million people vaccinated with the shot to date.
While the ... |
| Apr 5, 2021 | JOHNSON & JOHNSON
Johnson & Johnson : Expands Phase 2a Clinical Trial of COVID-19 Vaccine Candidate to Include Adolescents | New Brunswick, NJ - Johnson & Johnson (the Company) has begun vaccinating adolescent participants in the ongoing Phase 2a clinical trial for its COVID-19 vaccine candidate, developed by the Janssen Pharmaceutical Companies of Johnson &a... |
| Apr 2, 2021 | JOHNSON & JOHNSON
Johnson & Johnson : Expands Phase 2a Clinical Trial of COVID-19 Vaccine Candidate to Include Adolescents | Expansion of ongoing trial to include adolescents 12-17 years of age reflects commitment to people of all ages affected by pandemic
New Brunswick, NJ (April 2, 2021)- Johnson & Johnson (the Company) has begun vaccinating adolescent part... |
| Feb 18, 2021 | Should You Get Covid-19 Coronavirus Vaccines While Pregnant? | A health care worker administers a dose of the Pfizer-BioNtech COVID-19 coronavirus vaccine to a ... [+] pregnant woman at Clalit Health Services, in Israel. (Photo by JACK GUEZ/AFP via Getty Images)AFP via Getty Images |
| Feb 12, 2021 | CDPHE: At least 6 Boulder County residents have experienced adverse reaction to COVID-19 vaccine | At least six Boulder County residents have experienced an adverse reaction to a COVID-19 vaccination, according to Colorado Department of Public Health and Environment.
In a Friday email, CDPHE stated that at least six Boulder County reside... |
| Jan 23, 2021 | Moderna Covid-19 Vaccine: Here Is The Risk Of Severe Allergic Reactions | The CDC has published a report on the rate of anaphylaxis after getting the Moderna Covid-19 mRNA ... [+] vaccine. (Photo by Jonathan Wiggs/The Boston Globe via Getty Images)Boston Globe via Getty Images |
| Jan 16, 2021 | Answers to your 24 most pressing questions about the coronavirus vaccine, from side effects and costs to when you’ll be able to get one | Registered Nurse Stephanie Cal receives the COVID-19 vaccine at Long Island Jewish Medical Centre. Scott Heins/Getty Images
Coronavirus vaccines are the main chance the US has to dig itself out of the pandemic, and 10.6 million people have ... |
| Jan 7, 2021 | CDC: With nearly 5 million Americans vaccinated, just 29 have had confirmed allergic reactions | Diana Carolina, a pharmacist at Memorial Healthcare System, receives a Pfizer-BioNtech Covid-19 vaccine at Memorial Healthcare System, on December 14, 2020 in Miramar, Florida. Joe Raedle/Getty Images
The CDC has released its first set of d... |
| Nov 20, 2020 | To Guarantee Safety Of Covid-19 Vaccines, Prioritize Long-Term Studies | A medical syringe and vials in front of the COVID-19 word are seen in this creative photo taken on ... [+] 18 November 2020. The U.S. biotechnology company Moderna announced its experimental Covid-19 vaccine with 94.5% effectiveness, as the... |
| FDA & CDC “pause” J&J Covid-19 vaccine to launch inquiry into rare blood clot cases | Federal health officials are asking clinicians to “pause” dosing of Johnson & Johnson’s Covid-19 vaccine following reports of blood clots in six people out of the more than 6.8 million people vaccinated with the shot to date.
While the ... |
